文献速递炎症性肠病

维得利珠单抗水平、抗药抗体及α4β7占位与炎症性肠病患者应答的关联

Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
PubMed 文献 · Clin Gastroenterol Hepatol · 2017-12-07

该前瞻性研究纳入以色列2家三级医疗中心的106例炎症性肠病患者(67例克罗恩病、39例溃疡性结肠炎),于2014年9月至2017年3月接受维得利珠单抗治疗。第6周临床缓解者维得利珠单抗中位水平为40.2 μg/mL,高于活动性疾病者的29.7 μg/mL(P = .05);维持治疗期C反应蛋白正常者中位水平为21.8 μg/mL,高于C反应蛋白升高者的11.9 μg/mL(P = .0006)。外周血记忆T细胞α4β7整合素在治疗早期及维持期接近完全占位,与应答状态或药物水平无关。

要点

  • 第6周临床缓解率为45%(48/106),第14周为48%(50/106)。
  • 第6周缓解者维得利珠单抗中位水平40.2 μg/mL,高于活动性疾病者的29.7 μg/mL(P = .05)。
  • 维持期C反应蛋白正常者中位药物水平21.8 μg/mL,高于C反应蛋白升高者的11.9 μg/mL(P = .0006)。

核心结论

  • 在真实世界炎症性肠病患者的前瞻性研究中,维得利珠单抗药物水平与缓解及炎症标志物水平相关。
  • 无论血清药物水平或治疗应答如何,维得利珠单抗治疗患者几乎所有T细胞的α4β7整合素均被阻断。
  • 这些发现提示需要探索阻止维得利珠单抗应答的替代机制。

研究设计与样本

  • 前瞻性研究,纳入2014年9月至2017年3月以色列2家三级医疗中心的106例炎症性肠病患者(67例克罗恩病、39例溃疡性结肠炎)。
  • 在诱导和维持治疗前及治疗期间收集临床数据和血清样本,检测维得利珠单抗血清水平、抗维得利珠单抗抗体及炎症标志物。
  • 从部分患者指定谷浓度时间点获取外周血单个核细胞,分离CD3+ CD45RO+ T细胞(36份样本)与荧光标记维得利珠单抗孵育,用流式细胞术定量α4β7整合素饱和度。
  • 对非炎症性肠病对照(n = 6)、未接受维得利珠单抗治疗的炎症性肠病对照(n = 8)及接受维得利珠单抗治疗的炎症性肠病患者(n = 15)的肠黏膜固有层CD3+ CD45RO+ T细胞进行流式细胞术分析。

主要发现

  • 第6周48/106例(45%)达到临床缓解,第14周50/106例(48%)达到临床缓解。
  • 第6周临床缓解者维得利珠单抗中位水平为40.2 μg/mL,活动性疾病者为29.7 μg/mL(P = .05)。
  • 维持治疗期C反应蛋白正常者维得利珠单抗中位血清水平为21.8 μg/mL,高于C反应蛋白升高者的11.9 μg/mL(P = .0006)。
  • 所测其他临床结局与任何 examined 时间点的维得利珠单抗中位血清水平均无关联。
  • 诱导治疗期17%的患者检出抗维得利珠单抗抗体,维持治疗期为3%,但与临床结局无相关性。

关键数值与推荐

  • 临床缓解定义为Harvey-Bradshaw指数评分低于5分或Simple Clinical Colitis Activity Index评分≤3分。
  • 第6周临床缓解者维得利珠单抗中位水平40.2 μg/mL vs 活动性疾病者29.7 μg/mL(P = .05)。
  • 维持治疗期C反应蛋白正常者维得利珠单抗中位水平21.8 μg/mL vs C反应蛋白升高者11.9 μg/mL(P = .0006)。
  • 诱导治疗期抗维得利珠单抗抗体检出率17%,维持治疗期3%,与临床结局无相关性。
  • 健康及炎症性肠病对照肠道记忆T细胞α4β7表达72%(四分位距,56%-81%),维得利珠单抗治疗者游离α4β7可检出仅5.6%(四分位距,4.4%-11.2%)(P < .0001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: There are few data available on the real-life pharmacokinetic and pharmacodynamics features of vedolizumab, a monoclonal antibody against integrin α4β7. We performed a prospective study of patients with inflammatory bowel diseases (IBDs) treated with vedolizumab to determine serum drug concentrations, formation of antivedolizumab antibodies (AVAs), and integrin α4β7 saturation. METHODS: We performed a prospective study of 106 patients with IBD (67 with Crohn's disease and 39 with ulcerative colitis) treated with vedolizumab from September 2014 through March 2017 at 2 tertiary medical centers in Israel. Clinical data and serum samples were collected before and during induction and maintenance therapy. Clinical remission was defined as Harvey-Bradshaw index scores below 5 or as Simple Clinical Colitis Activity Index scores of 3 or less. We measured serum levels of vedolizumab, AVAs, and markers of inflammation. Peripheral blood mononuclear cells were obtained from some patients at designated trough time points and CD3+ CD45RO+ T cells were isolated from 36 samples. Cells were incubated with fluorescent-conjugated vedolizumab and flow cytometry was used to quantify α4β7 integrin saturation. We also performed flow cytometry analyses of CD3+ CD45RO+ lamina propria T cells isolated from intestinal mucosa of patients without IBD (non-IBD controls, n = 6), patients with IBD not treated with vedolizumab (untreated IBD controls, n = 8), and patients with IBD treated with vedolizumab (n = 15). RESULTS: Clinical remission was achieved by 48 of 106 patients (45%) by week 6 and 50 of 106 patients (48%) by week 14 of treatment. The median level of vedolizumab at week 6 was higher in patients in clinical remission (40.2 μg/mL) than in patients with active disease (29.7 μg/mL; P = .05). The median serum level of vedolizumab was significantly higher in patients with a normal level of C-reactive protein (21.8 μg/mL vedolizumab) vs the level in those with a high level of C-reactive protein (11.9 μg/mL vedolizumab) during maintenance treatment (P = .0006). The other clinical outcomes measured were not associated with median serum level of vedolizumab at any time point examined. AVAs were detected in 17% of patients during induction therapy and 3% of patients during maintenance therapy, but did not correlate with clinical outcomes. Flow-cytometry analysis of peripheral blood memory T cells (n = 36) showed near-complete occupancy of α4β7 integrin at weeks 2 and 14 and during the maintenance phase, regardless of response status or drug levels. Most intestinal CD3+CD45RO+ memory T cells of healthy and IBD controls expressed α4β7 (72%; interquartile range, 56%-81%). In contrast, free α4β7 was detectable on only 5.6% of intestinal memory cells (interquartile range, 4.4%-11.2%) (P < .0001) from vedolizumab-treated patients, regardless of response. CONCLUSIONS: In a prospective study of real-life patients with IBD, we associated vedolizumab drug levels with remission and inflammatory marker level. Integrin α4β7 was blocked in almost all T cells from patients treated with vedolizumab, regardless of serum level of the drug or response to treatment. These findings indicate a need to explore alternative mechanisms that prevent response to vedolizumab.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Ungar B, Kopylov U, Yavzori M, et al. Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2017. PMID: 29223444. doi:10.1016/j.cgh.2017.11.050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。